Impact of Antiplatelet and Anticoagulant Therapy on TBI Severity and Mortality in ICU Patients

Overview

This multicenter retrospective study evaluated the influence of preinjury antiplatelet and anticoagulant medications on traumatic brain injury (TBI) severity and 1-year mortality among ICU-treated patients. Findings suggest that anticoagulant use, particularly warfarin, is associated with increased mortality and higher intracranial injury burden, while antiplatelet therapy shows minimal impact on mortality.

Background

Traumatic brain injury (TBI) is a leading cause of mortality in young adults and a significant risk factor for morbidity and mortality in the elderly. The use of antiplatelet and anticoagulant medications has increased with aging populations, raising concerns about their role in TBI outcomes due to coagulopathy and hematoma progression. Various CT scoring systems, such as the Helsinki CT score, provide quantitative assessments of intracranial injury severity and prognosis in TBI patients. Prior studies have not fully separated the effects of medication-induced coagulopathy from radiological injury burden on mortality.

Data Highlights

The study included adult ICU-treated TBI patients admitted between 2003 and 2013 from four Finnish tertiary ICUs. Preinjury medication data were obtained from national prescription records. The Helsinki CT score was used to quantify intracranial injury burden. Mortality data were collected up to one year post-injury. The study excluded patients without admission non-contrast CT scans or Glasgow Coma Scale scores. Anticoagulant use, especially warfarin, was linked to increased mortality and higher Helsinki CT scores, indicating greater injury severity.

Key Findings

• Preinjury anticoagulant use independently predicts increased 1-year mortality in ICU-treated TBI patients.
• Warfarin anticoagulation is associated with a sixfold increase in TBI mortality compared to non-users.
• Direct oral anticoagulants (DOACs) do not significantly increase in-hospital mortality in mild TBI cases.
• Antiplatelet therapy shows minimal to no increase in mortality following TBI.
• Patients on anticoagulants exhibit higher intracranial injury burden as measured by the Helsinki CT score, suggesting medication-induced coagulopathy exacerbates injury severity.
• Antiplatelet and anticoagulant medications do not increase mortality in trauma patients without TBI, highlighting a specific interaction with brain injury.

Clinical Implications

Clinicians should recognize that preinjury anticoagulant therapy, particularly warfarin, significantly elevates mortality risk and intracranial injury severity in TBI patients admitted to the ICU. Careful assessment and management of coagulopathy are critical in this population. Antiplatelet therapy appears to have a limited impact on mortality, which may influence risk stratification and treatment decisions. Utilizing CT scoring systems like the Helsinki CT score can aid in quantifying injury burden and guiding prognosis.

Conclusion

Preinjury anticoagulant use, especially warfarin, is associated with increased intracranial injury severity and higher 1-year mortality in ICU-treated TBI patients, whereas antiplatelet therapy has minimal effect on outcomes. These findings underscore the importance of integrating medication history and radiological assessment in managing TBI patients.

References

1. Author/Source/Year -- Impact of Antiplatelet and Anticoagulant Therapy on Severity of Injury and Mortality Rates in ICU Patients with TBI